Hobson, James J ORCID: 0000-0003-2551-1774, Rannard, Steve P ORCID: 0000-0002-6946-1097, Owen, Andrew ORCID: 0000-0002-9819-7651 and Liptrott, Neill J ORCID: 0000-0002-5980-8966
(2020)
Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity.
Nanomedicine, 15 (14).
pp. 1361-1374.
Text
NE Immune Manuscript Final_R1.docx - Author Accepted Manuscript Download (475kB) |
Abstract
<jats:p> Aim: A preclinical safety assessment of a novel nanoemulsion drug-delivery system, initially developed to improve the posology of efavirenz (EFV), was conducted with a specific focus on possible immunological and hematological complications. Materials & methods: Assessment of common acute toxicities, such as complement activation and cytokine secretion, was performed using validated assays known to have good correlation with in vivo end points. Results & conclusion: Compared with a standard aqueous solution of EFV, the EFV nanoemulsion showed no significant effect on immune cell function or phenotype. Prolongation of activated partial thromboplastin time was observed for EFV-loaded nanoemulsions (88% at 4 μg/ml) as well as unloaded nanoemulsions (52%) highlighting the potential for drug-free anticoagulant activity and warranting further investigation of the mechanism and utility of these materials. </jats:p>
Item Type: | Article |
---|---|
Uncontrolled Keywords: | HIV, immunotoxicity, nanoemulsion, nanomedicine, preclinical, safety |
Depositing User: | Symplectic Admin |
Date Deposited: | 05 Jun 2020 08:04 |
Last Modified: | 18 Jan 2023 23:50 |
DOI: | 10.2217/nnm-2019-0447 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3089477 |